title: Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the safety of intravitreal ocriplasmin prospectively, reporting potential complications in patients with vitreomacular traction (VMT) alone or associated with macular hole (MH).
  
  
  METHODS
  Participants in this prospective, multicenter study, were 24 patients with VMT (17 with VMT alone and seven with MH combined with VMT). All patients were treated with a single ocriplasmin injection and followed-up prospectively at baseline, day 7, 28 and the last examination of the follow-up for each patient (mean ± SD: 64.2 ± 24.4 d, range: 40-145 d). Best-corrected visual acuity (BCVA) was assessed, and spectral-domain optical coherence tomography was performed at each visit while the percentage of resolution of VMT and the association with various potential adverse events were recorded and analyzed.
  
  
  RESULTS
  66.7% of patients presented VMT release at the end of the follow-up, while 28.6% exhibited MH closure. Severe adverse events, such as enlargement of preexisting MH and formation of lamellar MH, were observed in one and four cases, respectively and remained till the end of the follow-up. Moderate adverse events, such as ellipsoid zone disruption and subretinal fluid development, became evident seven days after injection, in four cases. Formation of cystoid macular edema (CME), not evident at baseline, was noticed in three cases at day 28 after injection. Mild adverse events, like vitreous floaters, photopsias, eye pain and foreign body sensation, were noticed at day 7 and resolved till the end of the follow-up.
  
  
  CONCLUSIONS
  Mild and moderate adverse events occurred mainly during the first week of the follow-up, while severe adverse events, such as the lamellar MH formation and CME at day 28 post injection were seen.
authors.affiliation: a 2nd Department of Ophthalmology, Ophthalmiatrion Athinon , Athens , Greece .
authors.forename: Irini P
authors.initials: IP
authors.lastname: Chatziralli
authors.affiliation: b 2nd Department of Ophthalmology, Henry Dunant Hospital , Athens , Greece .
authors.forename: George P
authors.initials: GP
authors.lastname: Theodossiadis
authors.affiliation: a 2nd Department of Ophthalmology, Ophthalmiatrion Athinon , Athens , Greece .
authors.forename: Efstratios
authors.initials: E
authors.lastname: Parikakis
authors.affiliation: c OMMA Eye Institute , Athens , Greece , and.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Datseris
authors.affiliation: d 2nd Department of Ophthalmology, University of Athens, Attikon Hospital , Athens , Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Theodossiadis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004487:Edema / Q000139:chemically induced; D058447:Eye Pain / Q000139:chemically induced; D005260:Female; D005341:Fibrinolysin / Q000009:adverse effects* / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D012167:Retinal Perforations / Q000188:drug therapy; D000267:Tissue Adhesions / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects*
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin
keywords: Complications; hole; ocriplasmin; retina; traction